Cellebrite DI Ltd. $CLBT Position Boosted by Strategic Advisors LLC

Strategic Advisors LLC lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 42.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,930 shares of the company’s stock after purchasing an additional 42,903 shares during the quarter. Strategic Advisors LLC owned 0.06% of Cellebrite DI worth $2,667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CLBT. Financial Management Professionals Inc. purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $28,000. CWM LLC boosted its position in Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after purchasing an additional 720 shares during the last quarter. Signaturefd LLC grew its stake in Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after purchasing an additional 819 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Cellebrite DI by 1,998.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after purchasing an additional 1,998 shares during the last quarter. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth about $38,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $16.01 on Thursday. The business has a fifty day moving average of $17.75 and a 200-day moving average of $17.00. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The firm has a market cap of $3.83 billion, a PE ratio of 51.65, a price-to-earnings-growth ratio of 2.31 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The company had revenue of $126.03 million for the quarter, compared to the consensus estimate of $122.98 million. During the same period in the prior year, the company earned $0.14 EPS. The firm’s revenue was up 17.9% compared to the same quarter last year. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CLBT shares. Needham & Company LLC raised their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Bank of America boosted their price target on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Finally, Lake Street Capital lifted their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.